Unicycive Therapeutics Analyst Ratings
Unicycive Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2023 | 492.11% | HC Wainwright & Co. | $7 → $4.5 | Maintains | Buy |
| 07/19/2023 | 821.05% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 06/30/2023 | 557.89% | EF Hutton | → $5 | Reiterates | Buy → Buy |
| 06/30/2023 | 821.05% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 06/26/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 06/20/2023 | 294.74% | Benchmark | → $3 | Reiterates | Speculative Buy → Speculative Buy |
| 05/17/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | Buy → Buy |
| 05/17/2023 | 557.89% | EF Hutton | → $5 | Reiterates | Buy → Buy |
| 04/21/2023 | 294.74% | Benchmark | $13 → $3 | Maintains | Speculative Buy |
| 04/03/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/31/2023 | 3057.89% | EF Hutton | → $24 | Reiterates | → Buy |
| 03/09/2023 | 557.89% | EF Hutton | → $5 | Initiates Coverage On | → Buy |
| 03/09/2023 | 952.63% | HC Wainwright & Co. | → $8 | Reiterates | → Buy |
| 03/09/2023 | 689.47% | Maxim Group | $3 → $6 | Maintains | Buy |
| 11/28/2022 | 952.63% | HC Wainwright & Co. | $9 → $8 | Maintains | Buy |
| 06/08/2022 | 1084.21% | HC Wainwright & Co. | → $9 | Initiates Coverage On | → Buy |
| 03/16/2022 | 294.74% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 08/09/2021 | 1676.32% | Roth Capital | → $13.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/16/2023 | 492.11% | HC Wainwright公司 | $7→$4.5 | 維護 | 買 |
| 07/19/2023 | 821.05% | HC Wainwright公司 | →$7 | 重申 | 購買→購買 |
| 2023/06/30 | 557.89% | EF Hutton | →$5 | 重申 | 購買→購買 |
| 2023/06/30 | 821.05% | HC Wainwright公司 | $8→$7 | 維護 | 買 |
| 2023/06/26 | 952.63% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 06/20/2023 | 294.74% | 基準 | →$3 | 重申 | 投機性買入→投機性買入 |
| 2023年05月17日 | 952.63% | HC Wainwright公司 | →$8 | 重申 | 購買→購買 |
| 2023年05月17日 | 557.89% | EF Hutton | →$5 | 重申 | 購買→購買 |
| 04/21/2023 | 294.74% | 基準 | $13→$3 | 維護 | 投機性購買 |
| 04/03/2023 | 952.63% | HC Wainwright公司 | →$8 | 重申 | →購買 |
| 03/31/2023 | 3057.89% | EF Hutton | →$24 | 重申 | →購買 |
| 03/09/2023 | 557.89% | EF Hutton | →$5 | 開始承保 | →購買 |
| 03/09/2023 | 952.63% | HC Wainwright公司 | →$8 | 重申 | →購買 |
| 03/09/2023 | 689.47% | Maxim集團 | $3→$6 | 維護 | 買 |
| 2022年11月28日 | 952.63% | HC Wainwright公司 | $9→$8 | 維護 | 買 |
| 06/08/2022 | 1084.21% | HC Wainwright公司 | →$9 | 開始承保 | →購買 |
| 03/16/2022 | 294.74% | Maxim集團 | →$3 | 開始承保 | →購買 |
| 08/09/2021 | 1676.32% | 羅斯資本 | →$13.5 | 開始承保 | →購買 |
What is the target price for Unicycive Therapeutics (UNCY)?
Uncycive Treeutics(UNCY)的目標價格是多少？
The latest price target for Unicycive Therapeutics (NASDAQ: UNCY) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $4.50 expecting UNCY to rise to within 12 months (a possible 492.11% upside). 15 analyst firms have reported ratings in the last year.
優尼西治療公司(納斯達克代碼：UNCY)的最新目標價是由HC Wainwright&Co.於2023年8月16日報道的。這家分析公司將目標價定為4.5美元，預計Uncy將在12個月內上漲至(可能上漲492.11)。過去一年，有15家分析公司公佈了評級。
What is the most recent analyst rating for Unicycive Therapeutics (UNCY)?
Uncycive Treeutics(Uncy)的最新分析師評級是什麼？
The latest analyst rating for Unicycive Therapeutics (NASDAQ: UNCY) was provided by HC Wainwright & Co., and Unicycive Therapeutics maintained their buy rating.
優尼西治療公司(納斯達克代碼：UNCY)的最新分析師評級由HC Wainwright&Co.提供，優尼西治療公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Unicycive Therapeutics (UNCY)?
Uncycive Treeutics(UNCY)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unicycive Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unicycive Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Unicycive Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Unicycive治療公司的上一次評級是在2023年8月16日提交的，所以你應該預計下一次評級將在2024年8月16日左右的某個時候提供。
Is the Analyst Rating Unicycive Therapeutics (UNCY) correct?
分析師對Uncycive Treeutics(Uncy)的評級正確嗎？
While ratings are subjective and will change, the latest Unicycive Therapeutics (UNCY) rating was a maintained with a price target of $7.00 to $4.50. The current price Unicycive Therapeutics (UNCY) is trading at is $0.76, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Uncycive Treeutics(Uncy)評級保持不變，目標價在7.00美元至4.50美元之間。Unicycive Treeutics(Uncy)目前的交易價格為0.76美元，超出了分析師的預測範圍。